The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
Open accessAbstract
This document provides clinical recommendations for the management of severe asthma. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the European Respiratory Society/American Thoracic Society Task Force's questions. The evidence was appraised using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of asthma experts, who made specific recommendations on six specific questions. After considering the balance of desirable and undesirable consequences, quality of evidence, feasibility, and acceptability of various interventions, the Task Force made the following recommendations: 1) suggest using anti-interleukin (IL)-5 and anti-IL-5 receptor α for severe uncontrolled adult eosinophilic asthma phenotypes; 2) suggest using a blood eosinophil cut-point ≥150 μL−1 to guide anti-IL-5 initiation in adult patients with severe asthma; 3) suggest considering specific eosinophil (≥260 μL−1) and exhaled nitric oxide fraction (≥19.5 ppb) cut-offs to identify adolescents or adults with the greatest likelihood of response to anti-IgE therapy; 4) suggest using inhaled tiotropium for adolescents and adults with severe uncontrolled asthma despite Global Initiative for Asthma (GINA) step 4–5 or National Asthma Education and Prevention Program (NAEPP) step 5 therapies; 5) suggest a trial of chronic macrolide therapy to reduce asthma exacerbations in persistently symptomatic or uncontrolled patients on GINA step 5 or NAEPP step 5 therapies, irrespective of asthma phenotype; and 6) suggest using anti-IL-4/13 for adult patients with severe eosinophilic asthma and for those with severe corticosteroid-dependent asthma regardless of blood eosinophil levels. These recommendations should be reconsidered as new evidence becomes available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Self-citationBritish Guideline on the Management of Asthma
British Thoracic Society Scottish Intercollegiate Guidelines Network (2008) · Thorax · doi:10.1136/thx.2008.097741 · Cited by 2,021
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationDetermining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Bleecker, E. R., FitzGerald, J. M., Chanez, P., Papi, A., Weinstein, S. F., Barker, P., Sproule, S., Gilmartin, G., Aurivillius, M., Werkström, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31324-1 · Cited by 1,406
Self-citationFitzGerald, J. M., Bleecker, E. R., Nair, P., Korn, S., Ohta, K., Lommatzsch, M., Ferguson, G. T., Busse, W. W., Barker, P., Sproule, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31322-8 · Cited by 1,397
Self-citationMepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Busse, W., Corren, J., Lanier, B. Q., McAlary, M., Fowler-Taylor, A., Cioppa, G. D., van As, A., & Gupta, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.117880 · Cited by 1,307
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationCastro, M., Zangrilli, J., Wechsler, M. E., Bateman, E. D., Brusselle, G. G., Bardin, P., Murphy, K., Maspero, J. F., O'Brien, C., & Korn, S. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00042-9 · Cited by 1,182
Self-citationTreatable traits: toward precision medicine of chronic airway diseases
Agusti, A., Bel, E., Thomas, M., Vogelmeier, C., Brusselle, G., Holgate, S., Humbert, M., Jones, P., Gibson, P. G., Vestbo, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01359-2015 · Cited by 1,083
Self-citationAfter asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Self-citationOral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma
Nair, P., Wenzel, S., Rabe, K. F., Bourdin, A., Lugogo, N. L., Kuna, P., Barker, P., Sproule, S., Ponnarambil, S., & Goldman, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703501 · Cited by 1,044
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationJuniper, E. F., Svensson, K., Mörk, A.-C., & Ståhl, E. (2005) · Respiratory Medicine · doi:10.1016/j.rmed.2004.10.008 · Cited by 929
Exploring the Effects of Omalizumab in Allergic Asthma: An Analysis of Biomarkers in the EXTRA Study
Hanania, N. A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D. F., Lal, P., Arron, J. R., Harris, J. M., & Busse, W. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1414oc · Cited by 901
Solèr, M., Matz, J., Townley, R., Buhl, R., O'Brien, J., Fox, H., Thirlwell, J., Gupta, N., & Della Cioppa, G. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00092101 · Cited by 827
Bousquet, J., Mantzouranis, E., Cruz, A. A., Aït-Khaled, N., Baena-Cagnani, C. E., Bleecker, E. R., Brightling, C. E., Burney, P., Bush, A., Busse, W. W., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.019 · Cited by 741
Self-citationReslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study
Castro, M., Mathur, S., Hargreave, F., Boulet, L.-P., Xie, F., Young, J., Wilkins, H. J., Henkel, T., & Nair, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0396oc · Cited by 716
Self-citationManagement of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Miravitlles, M., Hurst, J. R., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Papi, A., Rabe, K. F., Rigau, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00791-2016 · Cited by 683
Self-citationTiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Kerstjens, H. A. M., Engel, M., Dahl, R., Paggiaro, P., Beck, E., Vandewalker, M., Sigmund, R., Seibold, W., Moroni-Zentgraf, P., & Bateman, E. D. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208606 · Cited by 669
Gibson, P. G., Yang, I. A., Upham, J. W., Reynolds, P. N., Hodge, S., James, A. L., Jenkins, C., Peters, M. J., Marks, G. B., Baraket, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31281-3 · Cited by 662
Self-citationOmalizumab for asthma in adults and children
Normansell, R., Walker, S., Milan, S. J., Walters, E. H., & Nair, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003559.pub4 · Cited by 651
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease
Pavord, I. D., Chanez, P., Criner, G. J., Kerstjens, H. A. M., Korn, S., Lugogo, N., Martinot, J.-B., Sagara, H., Albers, F. C., Bradford, E. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708208 · Cited by 625
Self-citationChupp, G. L., Bradford, E. S., Albers, F. C., Bratton, D. J., Wang-Jairaj, J., Nelsen, L. M., Trevor, J. L., Magnan, A., & ten Brinke, A. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30125-x · Cited by 599
Ortega, H. G., Yancey, S. W., Mayer, B., Gunsoy, N. B., Keene, O. N., Bleecker, E. R., Brightling, C. E., & Pavord, I. D. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30031-5 · Cited by 559
Self-citationGuidelines for the diagnosis and management of asthma.
Berg, A. O., & Moy, J. G. (1993) · PubMed · Cited by 558
Castro, M., Wenzel, S. E., Bleecker, E. R., Pizzichini, E., Kuna, P., Busse, W. W., Gossage, D. L., Ward, C. K., Wu, Y., Wang, B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70201-2 · Cited by 488
Self-citationClarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma
Simpson, J. L., Powell, H., Boyle, M. J., Scott, R. J., & Gibson, P. G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1134oc · Cited by 482
Self-citationBrusselle, G. G., VanderStichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V., Verleden, G., Demedts, I. K., Verhamme, K., Delporte, A., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202698 · Cited by 477
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels
Bjermer, L., Lemiere, C., Maspero, J., Weiss, S., Zangrilli, J., & Germinaro, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.032 · Cited by 426
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma
Corren, J., Weinstein, S., Janka, L., Zangrilli, J., & Garin, M. (2016) · Chest · doi:10.1016/j.chest.2016.03.018 · Cited by 388
Kuo, C.-H. S., Pavlidis, S., Loza, M., Baribaud, F., Rowe, A., Pandis, I., Sousa, A., Corfield, J., Djukanovic, R., Lutter, R., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02135-2016 · Cited by 369
Self-citationPediatric severe asthma is characterized by eosinophilia and remodeling without TH2 cytokines
Bossley, C. J., Fleming, L., Gupta, A., Regamey, N., Frith, J., Oates, T., Tsartsali, L., Lloyd, C. M., Bush, A., & Saglani, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.01.059 · Cited by 316
Self-citationBusse, W. W., Bleecker, E. R., FitzGerald, J. M., Ferguson, G. T., Barker, P., Sproule, S., Olsson, R. F., Martin, U. J., Goldman, M., Yañez, A., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30406-5 · Cited by 314
Self-citationKhatri, S., Moore, W., Gibson, P. G., Leigh, R., Bourdin, A., Maspero, J., Barros, M., Buhl, R., Howarth, P., Albers, F. C., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.033 · Cited by 304
Self-citationKerstjens, H. A. M., Disse, B., Schröder-Babo, W., Bantje, T. A., Gahlemann, M., Sigmund, R., Engel, M., & van Noord, J. A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.039 · Cited by 276
What are minimal important changes for asthma measures in a clinical trial?
Santanello, N. C., Zhang, J., Seidenberg, B., Reiss, T. F., & Barber, B. L. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14a06.x · Cited by 275
Panettieri, R. A., Sjöbring, U., Péterffy, A., Wessman, P., Bowen, K., Piper, E., Colice, G., & Brightling, C. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30184-x · Cited by 235
Self-citationEosinophils in mucosal immune responses
Travers, J., & Rothenberg, M. E. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.2 · Cited by 205
Taylor, S. L., Leong, L. E. X., Mobegi, F. M., Choo, J. M., Wesselingh, S., Yang, I. A., Upham, J. W., Reynolds, P. N., Hodge, S., James, A. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1739oc · Cited by 186
Self-citationPrevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Hurst, J. R., Miravitlles, M., Papi, A. A., Rabe, K. F., Comas, D. R., et al. (2017) · doi:10.7892/boris.105695 · Cited by 168
Self-citationPrevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Hurst, J. R., Miravitlles, M., Papi, A., Rabe, K. F., Rigau, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02265-2016 · Cited by 164
Self-citationResponse to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
Casale, T. B., Chipps, B. E., Rosén, K., Trzaskoma, B., Haselkorn, T., Omachi, T. A., Greenberg, S., & Hanania, N. A. (2018) · Allergy · doi:10.1111/all.13302 · Cited by 158
RUSSELL, R. J., Chachi, L., FitzGerald, J. M., Backer, V., Olivenstein, R., Titlestad, I. L., Ulrik, C. S., Harrison, T., Singh, D., Chaudhuri, R., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30201-7 · Cited by 141
Self-citationA trial of clarithromycin for the treatment of suboptimally controlled asthma
Sutherland, E. R., King, T. S., Icitovic, N., Ameredes, B. T., Bleecker, E. R., Boushey, H. A., Calhoun, W. J., Castro, M., Cherniack, R. M., Chinchilli, V. M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.024 · Cited by 136
Self-citationStrunk, R. C., Bacharier, L. B., Phillips, B. R., Szefler, S. J., Zeiger, R. S., Chinchilli, V. M., Martínez, F. D., Lemanske, R. F., Taussig, L. M., Mauger, D. T., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.09.028 · Cited by 132
Szefler, S. J., Murphy, K. R., Harper, T. B., Boner, A. L., Laki, I., Engel, M., Azzi, G. E., Moroni-Zentgraf, P., Finnigan, H., & Hamelmann, E. H. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.014 · Cited by 118
Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function
Andersson, C. K., Adams, A., Nagakumar, P., Bossley, C. J., Gupta, A. K., Vries, D. D., Adnan, A., Bush, A., Saglani, S., & Lloyd, C. M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.022 · Cited by 113
Self-citationRandomised controlled trials in severe asthma: selection by phenotype or stereotype
Brown, T., Jones, T. L., Gove, K., Barber, C., Elliott, S., Chauhan, A., & Howarth, P. H. (2018) · European Respiratory Journal · doi:10.1183/13993003.01444-2018 · Cited by 112
Predictors of response to tiotropium versus salmeterol in asthmatic adults
Peters, S. P., Bleecker, E. R., Kunselman, S. J., Icitovic, N., Moore, W. C., Pascual, R. M., Ameredes, B. T., Boushey, H. A., Calhoun, W. J., Castro, M., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.08.003 · Cited by 109
Self-citationKerstjens, H. A. M., Moroni-Zentgraf, P., Tashkin, D. P., Dahl, R., Paggiaro, P., Vandewalker, M. L., Schmidt, H., Engel, M., & Bateman, E. D. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.06.013 · Cited by 108
A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
Hamelmann, E. H., Bernstein, J. A., Vandewalker, M. L., Moroni-Zentgraf, P., Verri, D., Unseld, A., Engel, M., & Boner, A. L. (2016) · European Respiratory Journal · doi:10.1183/13993003.01100-2016 · Cited by 108
Using Periostin as a Biomarker in the Treatment of Asthma
Izuhara, K., Ohta, S., & Ono, J. (2016) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2016.8.6.491 · Cited by 101
Blood eosinophil count and exacerbation risk in patients with COPD
Kerkhof, M., Sonnappa, S., Postma, D. S., Brusselle, G., Agustí, A. G. N., Anzueto, A. R., Jones, R. C. M., Papi, A. A., Pavord, I. D., Pizzichini, E., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00761-2017 · Cited by 89
Azithromycin for Bronchial Asthma in Adults: An Effectiveness Trial
Hahn, D. L., Grasmick, M., Hetzel, S., Yale, S. H., & on behalf of the AZMATICS (AZithroMycin-Asthma Trial In Community Settings) Study Group (2012) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2012.04.110309 · Cited by 69
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
Busse, W. W., Brusselle, G., Korn, S., Kuna, P., Magnan, A., Cohen, D., Bowen, K., Piechowiak, T., Wang, M., & Colice, G. (2018) · European Respiratory Journal · doi:10.1183/13993003.00948-2018 · Cited by 69
Odajima, H., Ebisawa, M., Nagakura, T., Fujisawa, T., Akasawa, A., Ito, K., Doi, S., Yamaguchi, K., Katsunuma, T., Kurihara, K., et al. (2016) · Allergology International · doi:10.1016/j.alit.2016.06.004 · Cited by 58
Lee, L. A., Yang, S., Kerwin, E., Trivedi, R., Edwards, L. D., & Pascoe, S. J. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.09.012 · Cited by 51
Lee, L. A., Briggs, A., Edwards, L. D., Yang, S., & Pascoe, S. J. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.10.009 · Cited by 43
Biologics for paediatric severe asthma: trick or TREAT?
Saglani, S., Bush, A., Carroll, W. D., Cunningham, S., Fleming, L., Gaillard, E. A., Gupta, A. K., Murray, C. S., Nagakumar, P., Paton, J. Y., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30045-1 · Cited by 41
Self-citationLevy, M. L., & Winter, R. J. D. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-206800 · Cited by 39
Severe asthma: looking beyond the amount of medication
Bush, A., Saglani, S., & Fleming, L. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30379-x · Cited by 33
Self-citationLetting the right one in: evaluating the generalisability of clinical trials
Shrimanker, R., Beasley, R. W., & Kearns, C. (2018) · European Respiratory Journal · doi:10.1183/13993003.02218-2018 · Cited by 11
Cited by
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02730-2021 · Cited by 537
Self-citationGlobal Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes
Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2205pp · Cited by 512
Self-citationEAACI Biologicals Guidelines—Recommendations for severe asthma
Agache, I., Akdis, C. A., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Chu, D. K., Del Giacco, S., Eiwegger, T., et al. (2021) · Allergy · doi:10.1111/all.14425 · Cited by 275
Asthma remission: what is it and how can it be achieved?
Thomas, D., McDonald, V. M., Pavord, I. D., & Gibson, P. G. (2022) · European Respiratory Journal · doi:10.1183/13993003.02583-2021 · Cited by 274
Self-citationAlpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper
Fieten, K. B., Drijver‐Messelink, M. T., Cogo, A., Charpin, D., Sokolowska, M., Agache, I., Taborda‐Barata, L. M., Eguiluz‐Gracia, I., Braunstahl, G. J., Seys, S. F., et al. (2022) · Allergy · doi:10.1111/all.15242 · Cited by 45
Metadata
- Authors
- Holguin, F., Cardet, J. C., Chung, K. F., Diver, S., Ferreira, D. S., Fitzpatrick, A., Gaga, M., Kellermeyer, L., Khurana, S., Knight, S., McDonald, V. M., Morgan, R. L., Ortega, V. E., Rigau, D., Subbarao, P., Tonia, T., Adcock, I. M., Bleecker, E. R., Brightling, C., Boulet, L.-P., Cabana, M., Castro, M., Chanez, P., Custovic, A., Djukanovic, R., Frey, U., Frankemölle, B., Gibson, P., Hamerlijnck, D., Jarjour, N., Konno, S., Shen, H., Vitary, C., & Bush, A.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-09-26
- Volume
- 55
- Issue
- 1
- Pages
- 1900588
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2974946068
- Cited by
- 629
- References
- 68
- FWCI
- 45.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.